The global Biliary Tract Cancers (BTCs) treatment market is expected to witness steady growth in the coming years, according to a new report published by a leading market research firm. The global Biliary Tract Cancers (BTCs) Treatment Market is anticipated to reach a market size of US$ 3.2 billion in 2023 and US$ 4.74 billion by exhibiting a CAGR of 4% from 2023 to 2033. From 2018 to 2022, the market for biliary tract cancers (BTCs) treatment experienced a 3% Growth.
BTCs are a group of rare and aggressive cancers that affect the biliary system, which includes the bile ducts, gallbladder, and liver. These cancers are often diagnosed at an advanced stage, making treatment challenging. However, recent advancements in diagnosis and treatment have improved the survival rates of patients with BTCs.
Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16764
According to the American Cancer Society, there were an estimated 12,000 new cases of BTCs in the United States in 2020. Additionally, the increasing adoption of minimally invasive procedures for the treatment of BTCs is also expected to drive market growth. The high cost of treatment and the lack of awareness among patients and healthcare providers about BTCs are some of the major challenges. However, the report suggests that government initiatives to raise awareness about BTCs and provide funding for research and development are expected to overcome these challenges in the coming years.
Key Takeaways from the Market Study
- The market for treatments for biliary tract cancers (BTCs) expanded at a CAGR of 3% from 2018 to 2022.
- Between 2023 and 2033, the market for biliary tract cancers (BTCs) treatment is anticipated to expand at a 4% CAGR.
- The market for treating biliary tract cancers (BTCs) is anticipated to reach US$ 4.74 billion by 2033.
- The injectable market share is the greatest, according to the Future Market Insights research.
- In the market for biliary tract cancers (BTCs) treatments, North America is anticipated to hold a 40% market share.
- The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Biliary Tract Cancers (BTCs) Treatment.” says an FMI analyst
Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16764
Market Competition
Key players in the market include companies such as Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, and BeiGene, along with healthcare providers and technology companies among other global players.
- In September 2022, Durvalumab (Imfinzi, AstraZeneca UK Limited) was granted approval by the Food and Drug Administration on September 2, 2022 for treating adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with gemcitabine and cisplatin. In the TOPAZ-1 (NCT03875235) trial, which was a randomized, double-blind, placebo-controlled, multiregional study, the efficacy of the treatment was evaluated. The trial enrolled 685 patients who had histologically confirmed locally advanced unresectable or metastatic BTC and who had not previously undergone systemic therapy for advanced disease.
The demographics of the trial showed that 56% were Asian, 37% were White, 2% were Black, and 4% were of other races, while 7% were Hispanic or Latino. In terms of gender, 50% were male and 50% were female, with a median age of 64 years (ranging from 20-85). 47% of the participants were 65 years or older. In the trial, 56% of patients had intrahepatic cholangiocarcinoma, 25% had gallbladder cancer, and 19% had extrahepatic cholangiocarcinoma.
More Insights Available
FMI, in its new offering, presents an unbiased analysis of the global Biliary Tract Cancers (BTCs) Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
Buy Now @ https://www.futuremarketinsights.com/checkout/16764
Key Segments Profiled in the Biliary Tract Cancers (BTCs) Treatment Industry Survey
Drug Class:
- Durvalumab
- Zanidatamab
- Ramucirumab
Route of Administration:
- Inhalation
- Intravenous
- Intranasal
- Subcutaneous
- Oral
- Parenteral
Molecule type:
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Small molecule
- Stem Cell
Product Type:
- Mono
- Combination
- Mono/Combination
About Us
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs